Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol-Remifentanil vs Sevoflurane-Sufentanil for Supratentorial Tumor Resection
NCT00389883Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2006
- Primary completion
- Jan 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of propofol and remifentanil in supratentorial neoplasm (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time from discontinuing anesthesia and extubation at 24 hours. Started Nov 2006; status: completed.
02
Drugs
propofolremifentanil
03
Conditions
supratentorial neoplasm
Beyond the preview
Go deeper on NCT00389883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389883.